Profile: AbbVie Inc (ABBV.K)

ABBV.K on New York Consolidated

62.43USD
23 Jan 2015
Change (% chg)

$-0.55 (-0.87%)
Prev Close
$62.98
Open
$63.66
Day's High
$63.66
Day's Low
$62.35
Volume
6,881,063
Avg. Vol
7,572,602
52-wk High
$70.76
52-wk Low
$45.50

Search Stocks

AbbVie Inc. (AbbVie) , incorporated on April 10, 2012, is a research-based pharmaceuticals company. The Company’s products are used to treat chronic autoimmune diseases, including rheumatoid arthritis, psoriasis, and Crohn’s disease; human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinson’s disease, and complications associated with chronic kidney disease and cystic fibrosis, among other health conditions, such as low testosterone. AbbVie also has a pipeline of new medicines, including more than 20 compounds or indications in Phase II or Phase III development across medical specialties as immunology, virology/liver disease, oncology, renal disease, neurological diseases and women’s health. It markets medicines in approximately 170 countries.

The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. AbbVie operates in one business segment—pharmaceutical products. Substantially all of AbbVie’s sales in the United States are to three wholesalers. Outside the United States, products are sold primarily to health care providers or through distributors, depending on the market served. In the United States, AbbVie’s products are generally sold directly to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies and independent retailers from distribution centers and public warehouses. Outside the United States, sales are made either directly to customers or through distributors, depending on the market served. Certain products are co-marketed or co-promoted with other companies.

As of June 30, 2014, AbbVie’s pipeline included more than 20 compounds or indications in Phase II and Phase III development individually or under collaboration or license agreements. Of these programs, 12 are in Phase III development or undergoing registrational review.

HUMIRA

HUMIRA is a biologic therapy administered as a subcutaneous injection. It is approved to treat Rheumatoid arthritis (moderate to severe), Psoriatic arthritis, Ankylosing spondylitis, Crohn's disease (moderate to severe), Plaque psoriasis (moderate to severe) and Juvenile idiopathic arthritis in North America and European Union; Ulcerative colitis (moderate to severe) in United States and European Union, and Axial spondyloarthritis and Pediatric Crohn's disease (severe) in European Union. HUMIRA is also approved in over 60 other markets, including Japan, Brazil, and Australia.

Metabolics/Hormones products

Metabolic and hormone products target a number of conditions, including hypothyroidism, testosterone deficiency and exocrine pancreatic insufficiency. These products include Synthroid, which is used in the treatment of hypothyroidism; AndroGel, a testosterone replacement therapy for males diagnosed with low testosterone that is available in two strengths: 1% and 1.62%, and Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency, a condition that occurs in patients with cystic fibrosis, chronic pancreatitis and several other conditions. AbbVie has the rights to sell Synthroid, AndroGel and Creon only in the United States.

Virology products

AbbVie's virology products include two products for the treatment of HIV infection, Kaletra and Norvir. Kaletra (also marketed as Aluvia in emerging markets) is a prescription anti-HIV-1 medicine that contains two protease inhibitors: lopinavir and ritonavir. Kaletra is used with other anti-HIV-1 medications to increase the chance of treatment response in people with HIV-1. Norvir (ritonavir) is a protease inhibitor that is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.

Endocrinology products

Lupron (also marketed as Lucrin and Lupron Depot) is a product for the palliative treatment of advanced prostate cancer, treatment of endometriosis and central precocious puberty, and for the preoperative treatment of patients with anemia caused by uterine fibroids. Lupron is approved for daily subcutaneous injection and one-month, three-month, four-month and six-month intramuscular injection.

Dyslipidemia products

AbbVie's dyslipidemia products address a range of metabolic conditions characterized by high cholesterol and/or high triglycerides. TriCor and TRILIPIX are fibric acid derivatives that are indicated as adjuncts to diet to reduce total cholesterol, LDL cholesterol, and triglyceride levels, and to increase HDL cholesterol levels. Niaspan is an extended release form of niacin that is indicated as an adjunct to diet to reduce total cholesterol, LDL cholesterol and triglyceride levels, and to increase HDL cholesterol levels. These products are primarily marketed to primary care physicians.

Other products

AbbVie's other products include Synagis, Anesthesia products, Duodopa, Duopa and Zemplar. Synagis is marketed by AbbVie outside of the United States that protects at-risk infants from severe respiratory disease or respiratory syncytial virus (RSV). Sevoflurane (sold under the trademarks Ultane and Sevorane) is an anesthesia product that AbbVie sells worldwide for human use. Duodopa is a levodopa-carbidopa intestinal gel (LCIG) marketed outside of the United States to treat advanced Parkinson's disease. The LCIG therapy has completed Phase III development for the United States under the name Duopa, and AbbVie is pursuing regulatory approval in the United States. Zemplar is a product sold across the world for the prevention and treatment of secondary hyperparathyroidism associated with Stage 3, 4, and 5 chronic kidney disease (CKD).

Company Address

AbbVie Inc

1 N Waukegan Rd
NORTH CHICAGO   IL   60064-1802
P: +1847.9327900
F: +1302.6555049

Company Web Links

Search Stocks